Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
881 stopped studies mapped to Malignant Intestinal Neoplasm and descendants · 90% state a reason
Over the 881 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04392050 | A Community-Based Educational Intervention to Improve Colorectal Cancer Screening | — | suspended | May 18, 2020 | Thomas Jefferson University | staffing | Other (stated, no rule matched) |
| NCT02885142 | Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic…(MUCEM) | N/A | terminated | Aug 31, 2016 | Assistance Publique Hopitaux De Marseille | difficulties to recruit all the patients | Enrollment / accrual |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05246839 | Informed Choice - Compass | — | terminated | Feb 18, 2022 | Exact Sciences Corporation | Business decision to terminate the study early. Primary endpoint will not be assessed. | Sponsor / business decision |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT06557278 | Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer(COMUNITY) | Phase 2 | withdrawn | Aug 16, 2024 | Mirror Biologics, Inc. | Redesign of protocol for primary end-point of overall survival | Other (stated, no rule matched) |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | — | terminated | Feb 23, 2024 | Young Adult Survivors United | Sponsoring organization no longer desired to recruit/maintain registry | Enrollment / accrual |
| NCT06730100 | CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable… | Phase 2 | withdrawn | Dec 12, 2024 | National Cancer Institute (NCI) | no accruals | Enrollment / accrual |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02982694 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant,… | Phase 2 | terminated | Dec 5, 2016 | Vall d'Hebron Institute of Oncology | The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is… | Efficacy / futility |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04827732 | Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in…(IMPARC) | N/A | terminated | Apr 1, 2021 | Washington University School of Medicine | Slow enrollment | Enrollment / accrual |
| NCT05350501 | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual…(CLAUDE) | Phase 2 | terminated | Apr 28, 2022 | Enterome | the study recruitment is significantly behind expectations as only one single patient has started… | Enrollment / accrual |
| NCT04693546 | Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test…(PREVENT) | — | suspended | Jan 5, 2021 | Metabiomics Corp | fundraising | Other (stated, no rule matched) |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab… | Phase 1 / Phase 2 | terminated | Feb 20, 2020 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | Phase 2 | terminated | Jan 10, 2023 | NuCana plc | A pre-planned initial analysis concluded that the study was unlikely to achieve its primary… | Other (stated, no rule matched) |
| NCT06410534 | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint… | Phase 2 | withdrawn | May 13, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H… | Phase 2 | withdrawn | Nov 15, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT00766142 | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis…(COCHISE) | Phase 2 | terminated | Oct 3, 2008 | Institut Bergonié | In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such,… | Efficacy / futility |
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal… | — | terminated | Dec 5, 2018 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT06217016 | Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer… | N/A | withdrawn | Jan 22, 2024 | The First Hospital of Jilin University | The ICCAUT-1 trial failed to demonstrate the superiority of the ICCAUT strategy in urinary… | Sponsor / business decision |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | terminated | May 27, 2016 | Eli Lilly and Company | The study was terminated due to business considerations | Sponsor / business decision |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and… | Phase 1 | terminated | Aug 14, 2025 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05743036 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | Phase 1 | terminated | Feb 24, 2023 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Study terminated due to change in therapeutic landscape. | Other (stated, no rule matched) |
| NCT04645797 | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With… | Phase 1 | terminated | Nov 27, 2020 | Apros Therapeutics, Inc | Study terminated prematurely due to internal corporate decision | Other (stated, no rule matched) |
| NCT05591534 | Endorectal Brachytherapy for Rectal Cancer(ICUREC) | Phase 2 | suspended | Oct 24, 2022 | University Hospital, Bordeaux | Unknown time frame for availability of new endorectal probes | Other (stated, no rule matched) |
| NCT05619172 | A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the… | Phase 2 | terminated | Nov 16, 2022 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic… | Phase 2 | terminated | Jun 6, 2018 | Patrick Boland | Drugs Unavailable | Other (stated, no rule matched) |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | — | terminated | Nov 14, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT02050737 | Plasma Biomarkers C-RAC, ICORG 12-27, V1 | — | terminated | Jan 31, 2014 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT05010850 | SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal…(SAFE-2) | N/A | terminated | Aug 18, 2021 | SafeHeal Inc | Voluntary and temporary suspension of enrollment. | Enrollment / accrual |
| NCT04786600 | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory… | Phase 2 | terminated | Mar 8, 2021 | University of Florida | slow accrual | Enrollment / accrual |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With…(ELEVATE CRC) | Phase 2 | terminated | Apr 15, 2022 | Gilead Sciences | Sponsor decision to terminate study | Sponsor / business decision |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | Phase 1 | terminated | Oct 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | Phase 1 | withdrawn | Nov 27, 2024 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT04964297 | Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With… | N/A | terminated | Jul 16, 2021 | Weill Medical College of Cornell University | Need for device upgrade. | Other (stated, no rule matched) |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | — | withdrawn | Nov 1, 2019 | ProgenaBiome | Company shifted focus | Sponsor / business decision |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT06895577 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer- | Phase 2 | withdrawn | Mar 26, 2025 | Sun Yat-sen University | Due to errors in the previously submitted modification, we request to withdraw it and will submit a… | Other (stated, no rule matched) |
| NCT04479436 | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer | Phase 2 | terminated | Jul 21, 2020 | Daiichi Sankyo | Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 28, 2025source: clinicaltrials